INTERFERON α-2B BY CONTINUOUS SUBCUTANEOUS INFUSION IN COMBINATION WITH RIBAVIRIN FOR TREATMENT-NAIVE GENOTYPE 1 HCV PATIENTS: 12 WEEK INTERIM ANALYSIS

被引：0
|
作者：
Muir, Andrew J. [1 ]
Bacon, Bruce R. [2 ]
Gitlin, Norman [4 ]
Kugelmas, Marcelo [3 ]
Tillman, Hans L. [1 ]
Grovender, Eric A. [5 ]
Van Antwerp, Bill [5 ]
Mische, Sarah [5 ]
Kwo, Paul Y. [6 ]
机构：
[1] Duke Clin Res Inst, Durham, NC USA
[2] St Louis Univ, Sch Med, St Louis, MO USA
[3] S Denver Gastroenterol, Englewood, CO USA
[4] Atlanta Gastroenterol Associates, Atlanta, GA USA
[5] Medtronic, Ventures & New Therapies, Minneapolis, MN USA
[6] Indiana Univ Sch Med, Indianapolis, IN USA
来源：
HEPATOLOGY | 2011年 / 54卷
关键词：
D O I：
暂无
中图分类号：
R57 [消化系及腹部疾病];
学科分类号：
摘要：
引用
收藏
页码：1439A / 1439A
页数：1
相关论文
共 50 条
  • [31] VIROLOGIC RESPONSE TO AN INTERFERON-FREE REGIMEN OF BI201335 AND BI207127, WITH AND WITHOUT RIBAVIRIN, IN TREATMENT-NAIVE PATIENTS WITH CHRONIC GENOTYPE-1 HCV INFECTION: WEEK 12 INTERIM RESULTS OF THE SOUND-C2 STUDY
    Zeuzem, Stefan
    Soriano, Vincent
    Asselah, Tarik
    Bronowicki, Jean-Pierre
    Ceausu, Emanoil
    Lohse, Ansgar W.
    Streinu-Cercel, Adrian
    Preotescu, Liliana
    Moussalli, Joseph
    Mullhaupt, Beat
    Schuchmann, Marcus
    Bourliere, Marc
    Calinas, Filipe
    Buti, Maria
    Roberts, Stuart K.
    Gane, Edward J.
    Stern, Jerry O.
    Nehmiz, Gerhard
    Bonaventura, Helge
    Boecher, Wulf O.
    Mensa, Federico J.
    HEPATOLOGY, 2011, 54 : 1436A - 1436A
  • [32] Antiviral response at week 12 following completion of treatment with albinterferon α-2b plus ribavirin in genotype 1, IFN-naive, chronic hepatitis C patients
    Zeuzem, S.
    Benhamou, Y.
    Bain, V.
    Shouva, D.
    Pianko, S.
    Flisiak, R.
    Grigorescu, M.
    Rehak, V.
    Yoshida, E.
    Kaita, K.
    Cronin, P.
    Pulkstenis, E.
    Subramanian, M.
    McHutchison, J.
    JOURNAL OF HEPATOLOGY, 2007, 46 : S293 - S293
  • [33] IL28B POLYMORPHISM AND KINETICS OF ANTIVIRAL ACTIVITY FOR ANA598 IN COMBINATION WITH PEGYLATED INTERFERON α2A PLUS RIBAVIRIN IN TREATMENT-NAiVE GENOTYPE-1 CHRONIC HCV PATIENTS
    Muir, Andrew J.
    Lawitz, Eric
    Rodriguez-Torres, Maribel
    Rustgi, Vinod K.
    Hassanein, Tarek
    Appleman, James R.
    Crowley, Constance A.
    Freddo, James L.
    McHutchison, John G.
    HEPATOLOGY, 2010, 52 (04) : 1200A - 1200A
  • [34] Interim (week 12) phase 2b virological efficacy and safety results of Albumin Interferon alpha 2b combined with ribavirin in genotype 1 chronic hepatitis C infection: the Australian cohort
    Pianko, S.
    Sievert, W.
    Subramanian, M.
    McHutchison, J.
    JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY, 2006, 21 : A313 - A313
  • [35] Insulin resistance and response to telaprevir plus peginterferon α and ribavirin in treatment-naive patients infected with HCV genotype 1
    Serfaty, Lawrence
    Forns, Xavier
    Goeser, Tobias
    Ferenci, Peter
    Nevens, Frederik
    Carosi, Giampiero
    Drenth, Joost P.
    Lonjon-Domanec, Isabelle
    DeMasi, Ralph
    Picchio, Gaston
    Beumont, Maria
    Marcellin, Patrick
    GUT, 2012, 61 (10) : 1473 - 1480
  • [36] Resistance Analysis of Hepatitis C Virus (HCV) from Genotype 1 and 4 Treatment-naive Subjects Receiving Samatasvir in Combination with Simeprevir and Ribavirin in a 12-week Phase II Clinical Trial
    Heinrich, Bianca
    Bilello, John P.
    Lawitz, Eric
    Rodriguez-Torres, Maribel
    Nguyen, Tuan T.
    Sheikh, Aasim M.
    Tobias, Hillel
    Galati, Joseph S.
    Hill, John M.
    Lok, Anna S.
    Nelson, David R.
    Vijgen, Leen
    Van Remoortere, Pieter
    Verloes, Rene
    Picchio, Gaston
    Patrick, Gloria Dubuc
    Seifer, Maria
    Mayers, Douglas L.
    HEPATOLOGY, 2014, 60 : 1153A - 1154A
  • [37] EFFICACY OF AN EIGHT-WEEK REGIMEN OF GRAZOPREVIR PLUS ELBASVIR WITH AND WITHOUT RIBAVIRIN IN TREATMENT-NAIVE, NONCIRRHOTIC HCV GENOTYPE 1B INFECTION
    Vierling, J. M.
    Kugelmas, M.
    Lawitz, E.
    Hwang, P.
    Robertson, M.
    Wahl, J.
    Barr, E.
    Haber, B.
    JOURNAL OF HEPATOLOGY, 2015, 62 : S618 - S618
  • [38] STUDY OF ABT-267 2-DAY MONOTHERAPY FOLLOWED BY 12-WEEK COMBINATION THERAPY IN TREATMENT-NAIVE PATIENTS WITH CHRONIC HCV GENOTYPE 1 INFECTION
    Epstein, M.
    Felizarta, F.
    Marbury, T.
    Badri, P.
    Mullally, V.
    Pilot-Matias, T.
    Liu, X.
    Setze, C. M.
    Campbell, A. L.
    Bernstein, B.
    JOURNAL OF HEPATOLOGY, 2013, 58 : S484 - S484
  • [39] Faldaprevir combined with pegylated interferon alfa-2a and ribavirin in treatment-naive patients with chronic genotype1 HCV: SILEN-C1 trial
    Sulkowski, Mark S.
    Asselah, Tarik
    Lalezari, Jacob
    Ferenci, Peter
    Fainboim, Hugo
    Leggett, Barbara
    Bessone, Fernando
    Mauss, Stefan
    Heo, Jeong
    Datsenko, Yakov
    Stern, Jerry O.
    Kukolj, George
    Scherer, Joseph
    Nehmiz, Gerhard
    Steinmann, Gerhard G.
    Boecher, Wulf O.
    HEPATOLOGY, 2013, 57 (06) : 2143 - 2154
  • [40] Effectiveness of Interferon α-2b and Ribavirin Combination Therapy in the Treatment of Naive Chronic Hepatitis C Patients in Clinical Practice
    Shehab, Thomas M.
    Fontana, Robert J.
    Oberhelman, Kelly
    Marrero, Jorge A.
    Su, Grace L.
    Lok, Anna S. F.
    CLINICAL GASTROENTEROLOGY AND HEPATOLOGY, 2004, 2 (05) : 425 - 431
12345